FDA-Approved Breast Cancer Drug Treatments

Share this content:
FDA-APPROVED BREAST CANCER TREATMENTS
Generic Brand Strength Form Usual Dose
ALKYLATING AGENTS
cyclophos-
phamide
25mg, 50mg tabs 1−5mg/kg/day
500mg, 1g, 2g pwd for IV inj after reconstitution 40−50mg/kg in divided doses over 2−5 days or 10−15mg/kg every 7−10 days or 3−5mg/kg twice weekly
thiotepa 15mg pwd for IV, intravesical, or intracavitary admin after reconstitution 0.3−0.4mg/kg IV once every 1−4wks
ANTIBIOTICS (CYTOTOXIC)
doxorubicin 10mg, 20mg, 50mg pwd for IV inj after reconstitution Monotherapy: 60−75mg/m² every 21 days
Combination therapy: 40−60mg/m² every 21−28 days
2mg/mL soln for IV inj
epirubicin Ellence 2mg/mL soln for IV infusion 100−120mg/m² on Day 1 or divided equally given on Days 1 and 8 of each cycle
ANTIESTROGEN
tamoxifen 10mg, 20mg tabs 20−40mg/day
Soltamox Oral 
Solution
10mg/
 
5mL
oral soln
toremifene Fareston 60mg tabs 60mg once daily
ANTIMETABOLITES
capecitabine Xeloda 150mg, 500mg tabs Monotherapy: 1250mg/m² twice daily
Combination therapy: Give with docetaxel 75mg/m² IV infused over 1hr every 3wks
fluorouracil 50mg/mL soln for IV inj 12mg/kg once daily for 4 successive days; max 800mg/day
gemcitabine Gemzar 200mg, 1g pwd for IV infusion after reconstitution 1250mg/m² on Days 1 and 8 of each 21‑day cycle
metho-
trexate
25mg/mL soln for IV, IM, intra-arterial, or intrathecal admin after dilution See drug monograph and manufacturer's full labeling
1g pwd for IV, IM, intra-arterial, or intrathecal admin after dilution
Trexall 5mg, 7.5mg, 10mg, 15mg scored tabs
ANTIMICROTUBULE AGENTS
docetaxel Taxotere 40mg/mL soln for IV infusion after dilution 60−100mg/m² once every 3wks
eribulin mesylate Halaven 0.5mg/mL soln for IV inj 1.4mg/m² IV inj over 2−5min on Days 1 and 8 of each 21‑day cycle
ixabepilone Ixempra 15mg, 45mg pwd for IV infusion after constitution and dilution 40mg/m² once every 3wks
paclitaxel Abraxane 100mg IV infusion; inj susp after reconstiution 260mg/m² every 3wks
Taxol 6mg/mL soln for IV infusion after dilution 175mg/m² every 3wks
vinblastine 10mg lyophilized pwd for IV inj or infusion after reconstitution 5.5−7.4mg/m² once weekly (see full labeling)
1mg/mL soln for IV inj or infusion
AROMATASE INHIBITOR
anastrozole Arimidex 1mg tabs 1mg once daily
exemestane Aromasin 25mg tabs 25mg once daily
letrozole Femara 2.5mg tabs 2.5mg once daily
ESTROGEN
conjugated estrogens Premarin 0.3mg, 0.45mg, 0.625mg, 0.9mg, 1.25mg tabs 10mg 3 times daily for at least 3mos
estradiol Estrace 0.5mg, 1mg, 2mg scored tabs 10mg 3 times daily for at least 3mos
ESTROGEN RECEPTOR ANTAGONIST
fulvestrant Faslodex 50mg/mL soln for IM inj Give by slow IM inj (over 1–2mins). Monotherapy: 500mg on Days 1, 15, 29, then once monthly thereafter. Combination therapy: give with palbociclib 125mg daily with food for 21 days, followed by 7 days off, or with abemaciclib 150mg twice daily; in pre/perimenopausal women: also treat with LHRH agonists.
GnRH ANALOGUE
goserelin Zoladex 3.6mg SC implant One 3.6mg implant every 28 days
HER2-TARGETED ANTIBODY-DRUG CONJUGATE
ado-trastuzumab emtansine Kadcyla 100mg, 160mg pwd for IV infusion after reconstitution Give by IV infusion only over 90mins. 3.6mg/kg max every 3wks (21‑day cycle) until disease progression or unacceptable toxicity. Subsequent infusions may be given over 30mins if previously tolerated.
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (HER2) INHIBITOR
pertuzumab Perjeta 420mg/
 
14mL (30mg/
 
mL)
soln for IV infusion Initially 840mg IV over 60mins, followed every 3wks thereafter by a dose of 420mg IV over 30–60mins, in combination with trastuzumab. MBC: also give with docetaxel. Neoadjuvant: give every 3wks for 3–6 cycles as part of one of the treatment regimens for EBC (see full labeling). Adjuvant: give every 3wks for 1yr (up to 18 cycles) or until disease recurrence or unacceptable toxicity, whichever occurs first, as part of EBC regimen (see full labeling).
trastuzumab Herceptin 440mg lyophilized pwd for IV infusion after reconstitution and dilution Initially 4mg/kg over 90mins, followed by 2mg/kg over 30mins weekly; administer until tumor progression. Adjuvant treatment, combination therapy: see full labeling.
KINASE INHIBITOR
abemaciclib Verzenio 50mg, 100mg, 150mg, 200mg tabs Combination: 150mg twice daily with fulvestrant or an aromatase inhibitor (see full labeling); in pre/perimenopausal women (in combination with fulvestrant): also treat with a gonadotropin-releasing hormone agonist. Monotherapy: 200mg twice daily. Both: continue until disease progression or unacceptable toxicity.
lapatinib Tykerb 250mg tabs HER2-positive (metastatic): 1250mg once daily on Days 1–21 continuously in combination with capecitabine 2000mg/m2/day on Days 1–14 in a repeating 21 day cycle; continue until disease progression or unacceptable toxicity. HR-positive, HER2-positive (metastatic): 1500mg once daily continuously in combination with letrozole 2.5mg once daily.
palbociclib Ibrance 75mg, 100mg, 125mg caps 125mg once daily for 21 days followed by 7 days off to complete a 28-day cycle, in combination with an aromatase inhibitor or with fulvestrant 500mg on Days 1, 15, 29, and once monthly thereafter. Pre/perimenopausal women (in combination with fulvestrant): also treat with LHRH agonists. See full labeling.
ribociclib Kisqali 200mg tabs 600mg once daily for 21 days followed by 7 days off to complete 28-day cycle. Take with letrozole 2.5mg once daily, or other aromatase inhibitors, throughout the 28-day cycle. See full labeling.
mTOR KINASE INHIBITOR
everolimus Afinitor 2.5mg, 5mg, 7.5mg, 10mg tabs 10mg once daily until disease progression or unacceptable toxicity.
POLY (ADP-RIBOSE) POLYMERASE INHIBITOR
olaparib Lynparza Tablets 100mg, 150mg tabs 300mg twice daily until disease progression or unacceptable toxicity; max 600mg daily.
PROGESTIN
megestrol acetate 20mg, 40mg scored tabs 40mg 4 times daily
SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM)
raloxifene Evista 60mg tabs 60mg once daily
NOTES

Key: MBC = metastatic breast cancer; EBC = early breast cancer
Not an inclusive list of medications and/or doses. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

(Rev. 6/2018)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs